UCrest Berhad has been granted its first patent in Taiwan for its flagship product iMedic™, an Artificial Intelligence (AI)-powered digital health platform. The patent granted covers AI-driven health management and its methods for telemedicine services, marking a major achievement in UCrest’s intellectual property journey and reinforcing its leadership in the global digital healthcare industry.
The patent protects the company’s innovations in AI powered diagnostics, personalised health analytics, and remote patient management, strengthening iMedic™’s position as a leading platform connecting patients, doctors, and healthcare institutions seamlessly across borders.
Pioneered in digital health, the core technologies of iMedic™ are powered by Artificial Intelligence (AI), Internet of Things (IoT), Blockchain, and data analytics integrated with a robust Electronic Medical Records (EMR) system. This combination of intelligent connectivity and secure data infrastructure enables iMedic™ to deliver highly personalised healthcare, continuous monitoring, and predictive analytics for preventive care and chronic disease management.
Over the past three years, UCrest has filed a total of seven patents covering various aspects of its AI health technologies and platform architecture. These filings include: 2 patents in the United States; 2 patents in Taiwan; 1 patent in China; 1 patent in Europe; and 1 global filing under the Patent Cooperation Treaty (PCT).
UCrest’s iMedic™ platform leverages advanced AI algorithms to analyse medical data, assist doctors in diagnosis, and enable continuous remote care. It has been deployed in multiple markets across Asia and beyond, supporting hospitals, clinics, and healthcare providers in delivering more efficient, personalised, and accessible healthcare services.
